<DOC>
	<DOCNO>NCT01558830</DOCNO>
	<brief_summary>Ranolazine effective remarkably safe agent treatment patient chronic stable angina , inhibition voltage gate potassium channel electrocardiogram ( EKG ) correct QT ( QTc ) prolongation property lead many question safety combine antiarrhythmic drug . The investigator propose study determine safety ranolazine patient chronic stable angina also take amiodarone . And conduct prospective single-center randomize single-blinded placebo control trial run large cardiology practice set Cardiovascular Consultants Nevada . The hypothesis difference ventricular arrhythmia burden . The primary outcome measurement ventricular arrhythmia episodes serial holter monitor serially acquire recording ( electrocardiogram , pacemaker implantable defibrillator ( ICD ) data , stress test data ) three month trial period .</brief_summary>
	<brief_title>Safety Amiodarone Ranolazine Together Patients With Angina</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>ischemic cardiac disease chronic anginal symptom amiodarone therapy cardiac condition pregnant nonEnglish speaking unstable angina baseline electrocardiogram ( EKG ) correct QT ( QTc ) &gt; 490ms severe thyroid dysfunction heart block without pacer system liver disease</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>amiodarone</keyword>
	<keyword>ranolazine</keyword>
	<keyword>safety</keyword>
	<keyword>arrhythmia</keyword>
</DOC>